Trump’s election threatens medical cooperation between U.S. and Cuba


In December, 2016, STAT, a website that reports on advances in the health and medical fields, published an article titled Trump’s election threatens medical cooperation between US and Cuba by Rob Waters. Focusing on Cuba’s somewhat unknown biotech industry, the article explored the uncertain future regarding cooperation between Cuba and the U.S.

Centering its discussion on a diabetes medication, Heberprot-P, which prevents amputations in a majority of patients with diabetic foot ulcers and has seen use around the world, and to a lesser extent a lung cancer drug called CimaVax, the article describes the history of the biotech industry in Cuba and the benefits of further expansion of trade in this area. Kegler Brown attorney Luis Alcalde is quoted in the article, saying that the possibility of Heberprot-P being approved for clinical use in the U.S. is “precisely the type of business project that puts America first.”

The Obama administration gave special permissions to U.S. companies to begin importing both drugs for testing, but due to Donald Trump’s comments during his campaign about rolling back the opening of relations with Cuba, there is uncertainty about whether this will continue once his administration begins.